Adprotech's lead drug candidate APT070, developed as treatment for rheumatoid arthritis and to improve organ transplant performance, will enter Phase II before end-2001 - Marketletter - September 17, 2001 - Business & Industry®

Report title: Adprotech's lead drug candidate APT070, developed as treatment for rheumatoid arthritis and to improve organ transplant performance, will enter Phase II before end-2001

from Business & Industry®
66 word report published September 17, 2001

Price $9.95 available for immediate download

Report Overview

About Business & Industry®

Source:

Marketletter

Geographic Region:

European Union (EUCX), United Kingdom (UNK), Western Europe (WEEX)

Industry(ies):

Pharmaceutical

Free Sample:

Click Here to Download

Format:

HTML

Price: $9.95

Free Sample

Questions about
this research?

Send page to a friend

Return to
Alacra Company Snapshot

Can't Decide?

Purchasing premium research sight unseen can be intimidating. At Alacra we want you to know what you are getting. Visit our FAQ or ask our Customer Service Team any questions about the report you are considering purchasing.